Health Condition 1: K746- Other and unspecified cirrhosis ofliver Health Condition 2: null- Patients suffering from end stage liver disease requiring Liver Transplantation.
Conditions
Interventions
Intervention1: Basiliximab
( 20 mg IV stat on post transplant Day 1 and 5 )( Two doses in total )
With Tacrolimus and Azathioprine: Basiliximab is an IL-2 receptor antibody used as an induction imm
Sponsors
Amrita Institute of Medical Sciences and Research
Dr Sudhindran
Eligibility
Inclusion criteria
Inclusion criteria: All patients more than 18 years who are recipients of primary liver allografts from a living donor are included in the study.
Exclusion criteria
Exclusion criteria: Deceased donor liver transplant recipients, Multiorgan transplants, ABO incompatable transplants, Recent steroid therapy, Recent chemotherapy, Intolerance to study medications, H/O CKD / current renal impairment where there is a pre-transplant decision to use basiliximab
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1)Biopsy proven acute rejection within 24 weeks following transplantation (Incidence and time to rejection). 2)Patient survival & graft survival. Timepoint: 24 weeks post transplant | — |
Secondary
| Measure | Time frame |
|---|---|
| Post transplant metabolic complications, infectious complications,graft functions, renal functions, duration of hospital stay, post transplant vascular/ biliary complications, Quality of lifeTimepoint: 24 weeks post transplant | — |
Countries
India
Contacts
Public ContactK Manikandan
Amrita Institute of Medical Sciences & Research
Outcome results
None listed